• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Methods of cost-effectiveness analysis: areas of consensus and debate.

作者信息

Luce B R, Simpson K

机构信息

Battelle Medical Technology Assessment and Policy (MEDTAP) Research Center, Arlington, Virginia, USA.

出版信息

Clin Ther. 1995 Jan-Feb;17(1):109-25. doi: 10.1016/0149-2918(95)80012-3.

DOI:10.1016/0149-2918(95)80012-3
PMID:7758053
Abstract

Methods of evaluating socioeconomic relationships have evolved over many years, and a number of specific approaches have been developed. Among the techniques available, cost-effectiveness analysis (CEA) has emerged as the most widely used and accepted method. Yet, despite considerable effort by the analytical community to refine this technique into one more useful for making health policy decisions, much debate and confusion still persist among analysts, readers, and policy-makers concerning methods standards and the overall usefulness of CEA in resource allocation decision making. Thus the purpose of this paper is to summarize, critically examine, and comment on existing recommended methods for socioeconomic evaluation of health care interventions. In particular, we examine an exhaustive set of component methods within the general area of cost-effectiveness and comment on areas of apparent consensus and debate. Our review reveals many areas of agreement and many yet to be resolved. Analysts generally agree on the components of the overall framework for an analysis; basic methodologic principles; the general treatment of costs; the principle of marginal analysis; the need for and general approach to discounting; the use of sensitivity analysis; the extent to which ethical issues can be incorporated; and the importance of choosing appropriate alternatives for comparison. The principal areas in which disagreement still persists are choice of study design, measurement and valuation of health outcomes including conversion of health outcomes to economic values, transformation of efficacy results into effectiveness outcomes, and the empirical measurement of costs.

摘要

相似文献

1
Methods of cost-effectiveness analysis: areas of consensus and debate.
Clin Ther. 1995 Jan-Feb;17(1):109-25. doi: 10.1016/0149-2918(95)80012-3.
2
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.质量调整生命年在儿科护理中缺乏质量:对已发表的儿童健康成本效用研究的批判性综述。
Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127.
3
Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders预防和治疗精神、神经及物质使用障碍的干预措施、政策和平台的成本效益及可负担性
4
Cost-effectiveness analysis in health care.医疗保健中的成本效益分析。
Hastings Cent Rep. 1989 Jul-Aug;19(4):8-13.
5
Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings.隐藏成本:资源有限环境下卫生干预措施成本效益分析的伦理问题。
Glob Public Health. 2017 Oct;12(10):1269-1281. doi: 10.1080/17441692.2016.1178319. Epub 2016 May 4.
6
Has the time come for cost-effectiveness analysis in US health care?美国医疗保健领域进行成本效益分析的时候到了吗?
Health Econ Policy Law. 2009 Oct;4(Pt 4):425-43. doi: 10.1017/S1744133109004885. Epub 2009 Feb 9.
7
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
8
Economic evaluation of interventions in health care.医疗保健干预措施的经济评估。
Nurs Stand. 2014 Nov 11;29(10):49-58. doi: 10.7748/ns.29.10.49.e9315.
9
Cost-effectiveness analysis in health care based on the capability approach.基于能力方法的医疗保健成本效益分析。
Gesundheitswesen. 2014 Oct;76(10):e39-43. doi: 10.1055/s-0033-1355421. Epub 2013 Oct 28.
10
Discounting in the economic evaluation of health care interventions.医疗保健干预措施经济评估中的贴现
Med Care. 1993 May;31(5):403-18. doi: 10.1097/00005650-199305000-00003.

引用本文的文献

1
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework.健康与医学中基于模型的决策的迭代方法指南:迭代决策框架。
Pharmacoeconomics. 2024 Apr;42(4):363-371. doi: 10.1007/s40273-023-01341-z. Epub 2023 Dec 29.
2
Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.比较效率研究(COMER):成本效益研究的荟萃分析
BMC Med Res Methodol. 2014 Dec 22;14:139. doi: 10.1186/1471-2288-14-139.
3
Cost effectiveness of a community based research project to help women quit smoking.
一个基于社区的帮助女性戒烟研究项目的成本效益
Tob Control. 2005 Feb;14(1):37-42. doi: 10.1136/tc.2003.005470.
4
The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios.基于疾病诊断相关分组(DRG)或国际疾病分类第九版(ICD - 9)编码或风险组分层的成本构建对所得成本效益比的影响。
Pharmacoeconomics. 2004;22(18):1209-16. doi: 10.2165/00019053-200422180-00005.
5
Breast scintigraphy today: indications and limitations.当今的乳腺闪烁扫描:适应证与局限性
Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S35-45. doi: 10.1007/s00259-004-1525-x. Epub 2004 Apr 23.
6
Decision analysis for the cost-effective management of recurrent colorectal cancer.复发性结直肠癌成本效益管理的决策分析
Ann Surg. 2001 Mar;233(3):310-9. doi: 10.1097/00000658-200103000-00003.
7
Common errors and controversies in pharmacoeconomic analyses.
Pharmacoeconomics. 1998 Jun;13(6):659-66. doi: 10.2165/00019053-199813060-00002.
8
The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?成本效益分析与成本效益分析(近乎)等同:事实还是谬误?
Pharmacoeconomics. 1998 Apr;13(4):389-96. doi: 10.2165/00019053-199813040-00002.
9
Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).发表于《药物经济学》的经济学评价的质量评估。头四年(1992年至1995年)。
Pharmacoeconomics. 1997 Dec;12(6):685-94. doi: 10.2165/00019053-199712060-00008.